- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00668356
Bioequivalence Study of Didanosine in Children Treated for HIV (ddI)
February 6, 2009 updated by: Assistance Publique - Hôpitaux de Paris
PKPOP Study of Didanosine in HIV Treated Children, at Fasting Period and During the Meal
The purpose of this study is to show that the administration of 400/mg/m2/day of didanosine(ddI) during the meal is bioequivalent to the administration of 240/mg/m2/day of didanosine during fasting, in HIV infected children treated by a ARV combination including ddI
Study Overview
Status
Suspended
Conditions
Intervention / Treatment
Detailed Description
The didanosine is one of the reverse transcriptase inhibitors.
This drug is efficient against the viral replication of the HIV.
Licensing for the children was obtained in June, 1992.
The main problem of the didanosine is its poor bioavailability: although gastro-resistant capsules were developed, its bioavailability remains dependent on alimentation.
Taking a meal 1-2 hours before the administration of ddI leads to a reduction of 50% of its bioavailability as well for the child as for the adult.
It is therefore recommended to take ddI during fasting period.
This regimen in some cases can decrease therapeutic observance.
A pharmacokinetic study of ddI will be conducted during the meal with 240 mg/m2/day during fasting period compare to 400 mg/m2/day during the meal.
26 patients, aged more than 6 years old, will be included and randomised in 2 groups.
The first group will take the standard dose of ddI during 28 days during fasting period (phase A), then the high dose during the meal during 28 days (phase B).
The second group will take first the phase B and secondly the phase A. Patients will be sequentially evaluated both after the first and the second period of treatment for pharmacokinetics and biological analysis.
Study Type
Interventional
Enrollment (Anticipated)
26
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris, France, 75015
- Hôpital Necker
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 15 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Children treated by the didanosine capsules more than 3 months
- viral load < 50 copies/ml
- written informed consent
- Normal renal function
Exclusion Criteria:
- Lack of observance
- Any treatments which can interact with ddI
- No written informed consent
- Weight > 60 kg
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
28 days 400 mg/m2/day during the meal 28 days 240 mg/m2/day during fasting
28 days 240 mg/m2/day during fasting 28 days 400 mg/m2/day during the meal
|
Active Comparator: 2
|
28 days 400 mg/m2/day during the meal 28 days 240 mg/m2/day during fasting
28 days 240 mg/m2/day during fasting 28 days 400 mg/m2/day during the meal
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PK parameters
Time Frame: 28 days
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Quality of life
Time Frame: 28 days
|
28 days
|
Biological analysis
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Stephane Blanche, MD, PhD, Assistance Publique - Hôpitaux de Paris
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion (Anticipated)
September 1, 2010
Study Completion (Anticipated)
December 1, 2010
Study Registration Dates
First Submitted
April 25, 2008
First Submitted That Met QC Criteria
April 28, 2008
First Posted (Estimate)
April 29, 2008
Study Record Updates
Last Update Posted (Estimate)
February 9, 2009
Last Update Submitted That Met QC Criteria
February 6, 2009
Last Verified
January 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antimetabolites
- Didanosine
Other Study ID Numbers
- P080101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on didanosine
-
Institut de Recherche pour le DeveloppementCompleted
-
Mansoura University Children HospitalCompleted
-
Tuberculosis Research Centre, IndiaIndian Council of Medical Research; National AIDS Control OrganisationUnknownTuberculosis | Human Immunodeficiency Virus InfectionsIndia
-
University of ParmaUniversity of Birmingham; Azienda Ospedaliero-Universitaria di Parma; Centro...CompletedCardiometabolic Health | Individual Variability in (Poly)Phenol MetabolismItaly
-
Clinical Trial Agency of HIV Study GroupCompleted
-
Bristol-Myers SquibbCompleted
-
National Institute of Allergy and Infectious Diseases...Bristol-Myers SquibbCompletedHIV InfectionsUnited States, Puerto Rico
-
Bristol-Myers SquibbCompleted
-
Peking Union Medical CollegeMinistry of Science and Technology of the People´s Republic of ChinaCompleted
-
French National Agency for Research on AIDS and...CompletedHIV InfectionVietnam